FDA Approved: HULIO — Supplemental Application (Biocon Biologics Inc)

View source ↗

Summary

The FDA approved a supplemental application for HULIO, Biocon Biologics' biosimilar adalimumab (adalimumab-fkJP).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Hidradenitis Suppurativa
• Juvenile Idiopathic Arthritis
• Plaque Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• HULIO (ADALIMUMAB-FKJP)

Snippet

SUPPL AP for HULIO (ADALIMUMAB-FKJP)